In the WHO classification,^[@bib1]^ double or triple-hit lymphoma depicts rare and aggressive lymphomas displaying *BCL2* and/or *MYC* and/or *BCL6* gene rearrangements that are categorized as B-cell lymphomas unclassified, with features intermediate between diffuse B-cell lymphoma and Burkitt lymphoma. Bacher *et al.*^[@bib2]^ described an interesting series of 10 cases of such neoplasms. In addition, they reported the two first cases displaying four different lymphoma-specific events (quadruple hit) involving the genes *MYC*, *BCL2*, *BCL6* and *CCND1*. We describe here a third case occurring in a 79-year-old male patient suffering from paraesthesias for 4 months who was referred for polyneuritis in a context of poor general condition. Clinical examination showed the presence of numerous axillary, supraclavicular, mediastinal and inguinal lymphadenopathies, neuro-meningeal invasion and skin infiltration. The biopsy of a left arm skin nodule revealed large proliferating cells (Ki-67 80%) stained by anti-CD20, BCL2 and BCL6 antibodies, CD10 and CD23 remaining negative, consistent with the diagnosis of diffuse large B-cell lymphoma (DLBCL), not otherwise specified. Blood cell counts showed 8.1 × 10^9^/l leukocytes, 13.2 g/dl hemoglobin, 166 × 10^9^/l platelets. LDH and β-2 microglobulin were elevated (989 U/I and 9.14 mg/l, respectively). Blood cell film examination showed the presence of 28% abnormal lymphocytes (medium sized, with intense basophilia, irregular nuclear contours, slightly clumped chromatin and frequent prominent nucleoli) suggestive of a high grade lymphoma. Flow cytometry revealed a lambda immunoglobulin light chain restriction. These cells expressed pan-B markers such as CD19, CD20, FMC7, CD22, with weak CD5 and CD43 positivity. CD10 and 23 were negative. Both the morphology and immunophenotype of the blood cells favored a pleomorphic mantle cell lymphoma (MCL) aggressive variant diagnosis. Cytogenetic study performed in the WBCs found a complex hyperdiploid karyotype (47 chromosomes, [Figure 1](#fig1){ref-type="fig"}) with a *t*(3;22) translocation involving the *BCL6* and *IGL* genes, a structural abnormality of chromosome 8 resulting in juxtaposition of 5′ *MYC* and *BCL2* in fluorescence *in situ* hybridization (with break of the MYC probe), a derivative chromosome 18 from a *t*(14;18) translocation with fusion of 5′*IGH* and *BCL2*, and a *t*(11;14) complex translocation involving *IGH* and *CCND1* ([Figure 2](#fig2){ref-type="fig"}). Other numeral (trisomy 12) and structural abnormalities (involving the 1, 7, 14 and 21 chromosomes) were also detected ([Figure 1](#fig1){ref-type="fig"}). Overexpression of cyclin D1 was detected in the WBCs by real-time quantitative PCR, as well as in the skin lesion using immunochemistry. Anti-SOX11 antibody staining was found to be negative. Chemotherapy combining rituximab, ifosfamide, cytosine arabinoside and intrathecal methotrexate was initiated, but the patient died 4 months after the diagnosis. This third case of quadruple-hit lymphoma underlines the complexity of the classification of such aggressive malignancies. Initial rearrangement of the *CCND1* gene characterizes MCL that may harbor in very rare cases additional rearrangements of *MYC* or *BCL6*, but histological transformation to typical large cell lymphoma is not retained in the WHO classification. In addition, cyclin D1 overexpression is considered to be a rare feature in DLBCL. Recently, Ok *et al.*^[@bib3]^ proposed to reclassify DLBCL with expression of cyclin D1, *CCND1* chromosomal rearrangement and CD5 positivity as an aggressive pleomorphic MCL variant. However, no observation of multiple lymphoma-specific gene rearrangements was described in that study. Juskevicius *et al.*^[@bib4]^ suggest the existence of a 'gray zone\' in which morphologic, clinical and genetic features are insufficient to segregate lymphomas with overexpression of cyclin D1/translocations involving *CCND1* between blastoid MCL and cyclin D1-positive DLBCL. Regarding the immunophenotyping and molecular data, our case is possibly a genetically unstable aggressive pleomorphic MCL variant, which acquired three additional genetic hits.
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